Accuracy of Post-Void Residual Urine Volume Measurement in Nigerian Men being evaluated for Prostate-related Lower Urinary Tract Symptoms: A Comparison of Ultrasonographic and Catheterization Methods

Introduction: The Post Void Residual Urine volume (PVRU) is frequently significant in patients with bladder outflow obstruction; especially in patients with enlarged prostate and prostatism. The PVRU forms an important part of radiological investigation. Accurate measurement of the residual urine volume changes observed serially over a period of time may indicate clinical progress. The purpose of this study was to evaluate the effect of pre-void bladder volume on PVRU measurements. Methods: A prospective study was conducted to determine the accuracy of PVRU measurement in patient presenting with lower urinary tract symptoms (LUTS). 50 patients with LUTS were assessed ultrasonographically for pre void and post void bladder volumes during the study period of March 2017 till August 2017. PVRU measurements done in patients with bladder filling sensation at moderate to full capacity resulted in high estimations of PVRU which was quite significant in this study. Results: There was significant difference in the estimated PVRU between patients having high initial premicturitional volume (546±144 ml) than those with lower or moderate filling volume (261±58 ml) with mean of 173 ml and 35 ml respectively. The difference in estimated PVRU was highly significant with p value of < 0.0001. Conclusions: Measurement of pre void urinary bladder volume with an uncomfortably full bladder results in high post micturitional (PMRU) values even in most patients without lower urinary tract symptoms which may be false-positive. We advise that initial or pre-void urine volume be measured when the patient has initial or moderate feeling of bladder fullness.

Download Full-text

The Effect of Anti-Muscarinic Agents on Post-Void Residual Urine Volume (PVR) in High Risk Male Patients with Lower Urinary Tract Symptoms (LUTS)

UroToday International Journal ◽

10.3834/uij.1939-4810.2008.06.24 ◽

2008 ◽

Author(s):

Alexandra E Rogers

Keyword(s):

Urinary Tract ◽

High Risk ◽

Lower Urinary Tract Symptoms ◽

Lower Urinary Tract ◽

Urine Volume ◽

Residual Urine Volume ◽

Urinary Tract Symptoms ◽

Male Patients ◽

Muscarinic Agents ◽

Lower Urinary

Download Full-text

Possibilities of phytotherapy in patients with lower urinary tract symptoms due to benign prostate enlargement

Urologicheskie vedomosti ◽

10.17816/uroved48969 ◽

2020 ◽

Vol 10 (4) ◽

pp. 317-323

Author(s):

Adel S. Al-Shukri ◽

Stanislav V. Kostyukov

Keyword(s):

Urinary Tract ◽

Lower Urinary Tract Symptoms ◽

Lower Urinary Tract ◽

Prostate Gland ◽

Urine Volume ◽

Good Tolerability ◽

Clinical Indicators ◽

Urinary Tract Symptoms ◽

Main Component ◽

Lower Urinary

The results of the use of the phytopreparation Tadimax in the treatment of 60 men with mild and moderate lower urinary tract symptoms (LUTS) developed as a result of benign enlargement of the prostate gland are presented. The average age of the patients was 66.5 3.8 years. Tadimax was prescribed 2 tablets 3 times a day, in courses of 7 days with 7 day breaks for 3 months (a total of 6 courses). The data obtained indicate high efficacy and good tolerability of treatment. A decrease in the severity of LUTS was noted in 59 (96.6%) patients, which was accompanied by significant changes in objective clinical indicators: a decrease in residual urine volume and an increase in urine flow rate. Tadimax is a combined preparation, which includes extracts of several medicinal plants, and the main component is Crinum latifolium. The therapeutic effect of Tadimax is based on anti-inflammatory, antiproliferative and immunotropic action.

Download Full-text

Prospective randomized controlled study directly comparing tadalafil and tamsulosin for male patients with lower urinary tract symptoms

10.1101/404566 ◽

2018 ◽

Author(s):

Takumi Takeuchi ◽

Satoshi Toyokawa ◽

Yumiko Okuno ◽

Noriko Ishida ◽

Masanari Yamagoe ◽

...

Keyword(s):

Urinary Tract ◽

Lower Urinary Tract Symptoms ◽

Lower Urinary Tract ◽

Urine Volume ◽

Maximum Flow ◽

Controlled Study ◽

Night Time ◽

Once Daily ◽

Urinary Tract Symptoms ◽

Lower Urinary

AbstractLower urinary tract symptoms are widespread in elderly men and often suggestive of benign prostatic hyperplasia (LUTS/BPH). A randomized, prospective, and open-labeled trial directly comparing the effects of tadalafil (a phosphodiesterase 5 inhibitor) 5 mg once daily and tamsulosin (an α1-blocker) 0.2 mg once daily for 12 weeks in LUTS/BPH patients was conducted. Data were recorded before randomization as well as at 4, 8, and 12 weeks after medication. Fifteen patients allocated tadalafil and 20 allocated tamsulosin completed 12 weeks of medication. Total IPSS, IPSS voiding, and IPSS-QOL scores declined with medication, but there was no difference between drugs. IPSS storage scores reduced more in the tamsulosin group than tadalafil group. OABSS did not decline significantly with medication. IIEF5 was maintained in the tadalafil group, but declined in the tamsulosin group. The maximum flow rate and post-void residual urine volume did not significantly change with medication. Daytime, night-time, and 24-hour urinary frequencies as well as the mean and largest daytime, night-time, and 24-hour voiding volumes per void did not significantly change with medication. In conclusion, tamsulosin was more effective to reduce storage symptoms than tadalafil. Tadalafil had the advantage of maintaining the erectile function.

Download Full-text

The Add-On Effect of Solifenacin for Patients with Remaining Overactive Bladder after Treatment with Tamsulosin for Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Obstruction

Advances in Urology ◽

10.1155/2010/205251 ◽

2010 ◽

Vol 2010 ◽

pp. 1-5 ◽

Cited By ~ 5

Author(s):

Naoya Masumori ◽

Taiji Tsukamoto ◽

Masahiro Yanase ◽

Hiroki Horita ◽

Masaharu Aoki

Keyword(s):

Urinary Tract ◽

Overactive Bladder ◽

Symptom Score ◽

Lower Urinary Tract Symptoms ◽

Lower Urinary Tract ◽

Urine Volume ◽

Real Life ◽

Benign Prostatic Obstruction ◽

Urinary Tract Symptoms ◽

Lower Urinary

Objectives. To investigate the add-on effect of solifenacin for Japanese men with remaining overactive bladder (OAB) symptoms after tamsulosin monotherapy for lower urinary tract symptoms (LUTS) suggestive of benign prostatic obstruction (BPO) in real-life clinical practice.Methods. Patients aged ≥ 50 having remaining OAB symptoms (≥ 3 of OAB symptom score (OABSS) with ≥2 of urgency score) after at least 4 weeks treatment by 0.2 mg of tamsulosin for BPO/LUTS received 2.5 or 5.0 mg of solifenacin for 12 weeks. The International Prostate Symptom Score (IPSS), QOL index and OABSS, maximum flow rate (Qmax) and postvoid residual urine volume (PVR) were determined.Results. A total of 48 patients (mean age 72.5 years) completed the study. There were significant improvement in IPSS (15.1 to 11.2) and QOL index (4.2 to 3.0) by add-on of solifenacin. Although the IPSS storage symptom score was significantly improved, there were no changes observed in the IPSS voiding symptom score. The OABSS showed significant improvement (8.0 to 4.8). No changes were observed in Qmax and PVR.Conclusions. Under the supervision of an experienced urologist, the additional administration of solifenacin to patients with BPO/LUTS treated with tamsulosin, is effective in controlling remaining OAB symptoms.

Download Full-text